Why We're Not Concerned About Eiken Chemical Co., Ltd.'s (TSE:4549) Share Price

With a price-to-earnings (or "P/E") ratio of 31.3x Eiken Chemical Co., Ltd. (TSE:4549) may be sending very bearish signals at the moment, given that almost half of all companies in Japan have P/E ratios under 12x and even P/E's lower than 8x are not unusual. However, the P/E might be quite high for a reason and it requires further investigation to determine if it's justified.

Eiken Chemical hasn't been tracking well recently as its declining earnings compare poorly to other companies, which have seen some growth on average. One possibility is that the P/E is high because investors think this poor earnings performance will turn the corner. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

Check out our latest analysis for Eiken Chemical

pe-multiple-vs-industry
TSE:4549 Price to Earnings Ratio vs Industry April 8th 2025
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Eiken Chemical .
Advertisement

Does Growth Match The High P/E?

The only time you'd be truly comfortable seeing a P/E as steep as Eiken Chemical's is when the company's growth is on track to outshine the market decidedly.

If we review the last year of earnings, dishearteningly the company's profits fell to the tune of 21%. The last three years don't look nice either as the company has shrunk EPS by 59% in aggregate. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.

Turning to the outlook, the next three years should generate growth of 21% per year as estimated by the one analyst watching the company. That's shaping up to be materially higher than the 9.7% per annum growth forecast for the broader market.

With this information, we can see why Eiken Chemical is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.

The Key Takeaway

While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.

As we suspected, our examination of Eiken Chemical's analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. At this stage investors feel the potential for a deterioration in earnings isn't great enough to justify a lower P/E ratio. Unless these conditions change, they will continue to provide strong support to the share price.

We don't want to rain on the parade too much, but we did also find 1 warning sign for Eiken Chemical that you need to be mindful of.

If P/E ratios interest you, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

Valuation is complex, but we're here to simplify it.

Discover if Eiken Chemical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:4549

Eiken Chemical

Engages in the manufacture and sale of clinical diagnostics in Japan.

Excellent balance sheet with proven track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
GANX logo
Lou_Basenese on Gain Therapeutics ·

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Fair Value:US$7.675.1% undervalued
13 users have followed this narrative
0 users have commented on this narrative
12 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.2535.6% undervalued
29 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative
TE
BUSER logo
TechMegaTrends on Bambuser ·

Bambuser is today the only listed company in Europe that simultaneously possesses an 85% gross margin, proprietary AI infrastructure for the

Fair Value:SEK 238.2690.3% undervalued
14 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative
HE
HedgeY
CSTM logo
HedgeY on Constellium ·

Constellium jet another cyclical aluminum processor, or a mispriced aluminum platform?

Fair Value:US$3410.2% undervalued
3 users have followed this narrative
0 users have commented on this narrative
2 users have liked this narrative

Updated Narratives

GO
NLBR logo
GoranLagea on Nova Ljubljanska Banka d.d ·

Nova Ljubljanska Banka d.d. future looks bright with a profit margin change of 38%

Fair Value:€36035.3% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
ELRIDGE logo
Anthony_Lee on Elridge Energy Holdings Berhad ·

Elridge Sees Quiet Accumulation as Urusharta Builds Position

Fair Value:RM 1.4537.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AL
alexbarongo
CRDB logo
alexbarongo on CRDB Bank ·

Critical analysis of CRDB Bank Tanzania (DSE: CRDB).CRDB Bank Tanzania — Critical Investment Analysis

Fair Value:TSh2.59k15.0% overvalued
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TR
tripledub
MSFT logo
tripledub on Microsoft ·

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

Fair Value:US$3950.5% undervalued
45 users have followed this narrative
3 users have commented on this narrative
42 users have liked this narrative
RO
Robbo
TSLA logo
Robbo on Tesla ·

The academically fascinating Tesla

Fair Value:US$301.1k% overvalued
38 users have followed this narrative
11 users have commented on this narrative
32 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$587.3133.1% undervalued
1357 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative